Search Results
Nov 04, 2025, 08:00 ET Security Control Management Charts the Course for Secure by Design Infrastructure in Dynamic Threat Environment, Industry Experts Reveal at InfoSec World 2025
validation. Integrate security with agile workflows, such as DevSecOps, Continuous Integration and Continuous Delivery/Deployment (CI/CD), Infrastructure as Code (IaC), and Governance, Risk and Compliance (GRC) tools, providing an end-to-end compliance solution built for agile workflows.
More news about: Sicura
Nov 04, 2025, 07:30 ET Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
either as a monotherapy, or in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation
More news about: Actinium Pharmaceuticals, Inc.
Nov 04, 2025, 06:20 ET Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
Antibody–Drug Conjugates (ADCs) currently hold 5% share, but emerging candidates targeting BCMA and CD46 are projected to double market share by 2030. By Route of Administration
More news about: DataM Intelligence 4 Market Research LLP
Nov 04, 2025, 01:06 ET American Binary Partners with Oracle to Deliver Quantum-Resistant VPN for Enterprise and Defense Sectors
their solutions available to customers in every OCI region globally. Oracle Cloud Marketplace offers a continuous integration/continuous deployment (CI/CD) pipeline for delivering updates and new features directly to customers, wherever they are. Defense
More news about: American Binary
Nov 03, 2025, 20:58 ET 口頭報告！維立志博5項血液腫瘤領域研究成果重磅登陸2025 ASH年會
phase I/II, open-label, multicenter, dose escalation and expansion study of LBL-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma摘要號：91報告類型：口頭報告報告時間：美國東部時間2025.12.06 9:30 AM – 9:45
More news about: 維立志博
Nov 03, 2025, 17:31 ET Chronic Progressive Multiple Sclerosis Market to Witness Accelerated Expansion During the Forecast Period (2025-2034) Due to Strong Pipeline and Advanced Therapeutic Strategies | DelveInsight
needs, particularly in progressive multiple sclerosis. LEMTRADA (alemtuzumab), developed by Sanofi, is a CD52-targeting monoclonal antibody approved for RRMS and active SPMS, though not recommended for CIS due to safety concerns. In the U.S., it is distributed
More news about: DelveInsight Business Research, LLP
Nov 03, 2025, 16:05 ET AAVivo, Inc. to Present at Society for Immunotherapy of Cancer 2025
adeno-associated viruses (AAV) with capsids containing T cell-targeting (TCeT) moieties to produce CD19-specific CAR-T cells in patients. Preclinical data to date suggest that AVO-100 can be used to generate CD19-specific T cells from non-activated T cells in human PBMCs both in vitro and in vivo
More news about: AAVivo, Inc.
Nov 03, 2025, 13:31 ET Recordati Rare Diseases to Share New Data at the American Society of Hematology (ASH) Meeting
detailing advances in Castleman disease (CD), cold agglutinin disease (CAD)/cold agglutinin syndrome (CAS), and immune-related complications of CAR T-cell therapy. Highlights include a report on the development of an artificial intelligence (AI) model that evaluates CD tissue samples; an analysis of the morbidity
More news about: Recordati
Nov 03, 2025, 12:16 ET Incredibuild Acquires AI Startup Kypso to Accelerate Code Development Pipelines in the AI-Native Era
Acquisition bolsters Incredibuild's mission to accelerate the entire CI/CD pipelines and power AI-enabled engineering TEL AVIV, Israel, Nov. 3, 2025
More news about: Incredibuild
Nov 03, 2025, 10:00 ET Principal® joins the Council for Disability Income Awareness
20253 Pensions & Investments, 2024 MEDIA CONTACTColby Gray, CD+M CommunicationsThe Council for Disability Income [email protected]
More news about: The Council for Disability Income Awareness
Nov 03, 2025, 09:15 ET CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
inhibitor, chemotherapy + autologous hematopoietic stem cell transplantation, and CD3/CD20 bispecific antibody therapy; another FL patient had failed immunochemotherapy + autologous hematopoietic stem cell transplantation and CD19 CAR-T therapy. The peak copy number of expansion in these three patients reached
More news about: CARsgen Therapeutics
Nov 03, 2025, 09:01 ET Orna Therapeutics Announces Multiple Presentations Supporting its in vivo CAR Programs for Autoimmune Diseases at the 67th American Society of Hematology Annual Meeting
ASH from our NHP studies for our CD19 and BCMA panCAR programs," said Joseph Bolen, Ph.D., Chief Executive Officer of Orna Therapeutics. "Data to be presented continues to demonstrate the best-in-class nature of our in vivo CAR platform in NHP for both our anti-CD19 and our anti-BCMA programs. As
More news about: Orna Therapeutics
Nov 03, 2025, 09:00 ET Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting
mutations.1,3 Enzomenib reduced the expression of the leukemia-associated genes HOXA9 and MEIS1, and increased the expression of the differentiation gene CD11b in human acute leukemia cell lines with MLL rearrangements and NPM1 mutation.4,5 The safety and efficacy of enzomenib is currently being
More news about: Sumitomo Pharma America
Nov 03, 2025, 08:30 ET Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
either as a monotherapy, or in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation
More news about: Actinium Pharmaceuticals, Inc.
Nov 03, 2025, 08:05 ET INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
0 was counted against the efficacy endpoint. Treatment with INO-3107 generated a strong immune response in the trial, inducing activated CD4 T cells and activated CD8 T cells with lytic potential. T cell responses were also observed at Week 52, indicating a persistent cellular memory response. INO-3107
More news about: INOVIO Pharmaceuticals, Inc.
Nov 03, 2025, 08:00 ET PetSafe Appoints Max Rangel as Chief Executive Officer
2025 /PRNewswire/ -- PetSafe, a global leader in pet care products and solutions and a portfolio company of Clayton, Dubilier & Rice (CD&R), today announced the appointment of Max Rangel as Chief Executive Officer, effective November 10, 2025. Mr. Rangel, a proven consumer products leader
More news about: PetSafe
Nov 03, 2025, 07:15 ET ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Nov 03, 2025, 07:00 ET Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
all-oral combination of selinexor 40 mg, pomalidomide and dexamethasone (SPd40) in patients with previously treated multiple myeloma who received an anti-CD38 in their immediate prior line of therapy. Anticipated Catalysts and Operational
More news about: Karyopharm Therapeutics Inc.
Nov 03, 2025, 06:30 ET Coeur Announces Acquisition of New Gold to Create a New, All North American Senior Precious Metals Producer
https://www.sedarplus.ca/csaparty/records/document.html?id=830b181741852e3fbae8f0bbde1c5d1322916fbc490192f57cd368fe27d666af. Additional information regarding the persons who may be deemed participants and their
More news about: New Gold Inc.
Nov 02, 2025, 23:12 ET Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
durvalumab + chemotherapy) First-line PD-L1–positive head and neck squamous cell carcinoma in combination with ligufalimab (CD47) (compared to pembrolizumab) In the challenging area of cold tumors, ivonescimab has received its fourth
More news about: Akeso, Inc.
Oct 31, 2025, 13:51 ET Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain receive the 2025 Merkin Prize at the Broad Institute for chimeric antigen receptor (CAR) T-cell therapy
their roles in pioneering CAR T-cell therapy. Sadelain talked about the early stages of the development of CAR molecules and the selection of the protein CD19 as a therapeutic target in CAR T-cell therapy. Levine detailed the process of turning CAR T-cell therapy from a technology developed in academic labs
More news about: Broad Institute
Oct 31, 2025, 12:32 ET InsCorp, Inc. Reports EPS Growth of 23% Y/Y in 3Q25
growth in interest-bearing transaction balances of 31% and non-interest bearing deposit growth of 14% over the past year. Total CD balances grew 10% Y/Y in 3Q25 and decreased to 58% of deposits compared to 60% a quarter vs. 61% a year ago. Non-interest bearing and interest-bearing
More news about: INSBANK
Oct 31, 2025, 07:49 ET AbbVie Reports Third-Quarter 2025 Financial Results
(upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD). The updated indication statement allows the use of Rinvoq prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of
More news about: AbbVie
Oct 30, 2025, 16:54 ET BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M
from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation
More news about: BioVaxys Technology Corp.
Oct 30, 2025, 16:44 ET PEOPLES FINANCIAL SERVICES CORP. Reports Unaudited Third Quarter and Year to Date 2025 Earnings
30, 2025, and December 31, 2024, respectively. As part of strategic balance sheet management initiatives, the Company reduced its higher rate brokered CD portfolio by $94.2 million during the first nine months of 2025. The Company's deposit base is diversified and consisted of
More news about: Peoples Financial Services Corp.